SEC Form 10-Q filed by Bio-Techne Corp
$TECH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $73.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/21/2025 | $70.00 | Neutral → Buy | Citigroup |
| 7/22/2025 | $65.00 | Overweight | Stephens |
| 7/9/2025 | $65.00 | Buy | TD Cowen |
| 5/30/2025 | $59.00 | Overweight | Wells Fargo |
| 4/9/2025 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/18/2025 | $75.00 | Outperform | Evercore ISI |
| 2/19/2025 | $88.00 → $68.00 | Outperform → Neutral | Robert W. Baird |
SCHEDULE 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
10-Q - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
RBC Capital Mkts upgraded Bio-Techne from Sector Perform to Outperform and set a new price target of $73.00
Citigroup upgraded Bio-Techne from Neutral to Buy and set a new price target of $70.00
Stephens resumed coverage of Bio-Techne with a rating of Overweight and set a new price target of $65.00
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
Fully defined, synthetic ECM designed to improve reproducibility and reduce lot-to-lot variabilitySupports standardization of scalable 3D stem cell and organoid workflowsSynthetic alternative to traditional matrices, enabling consistent performance while aligning with regulatory and translational initiativesMINNEAPOLIS, Feb. 2, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ Synthetic Hydrogel, a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's estab
Detects low-abundance proteins in blood at femtogram concentrations for earlier disease insightsSupports research in Alzheimer's, ALS, MS, Parkinson's Disease, and Traumatic Brain Injury with validated biomarkersAutomated immunoassay workflow reduces variability; total runtime is under three hoursMINNEAPOLIS, Jan. 28, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform. Early detection of neurodegenerative disease biomarkers has historically been limited by their extremely low abundance in accessible bioflu
MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CST to review its second quarter fiscal 2026 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 4, 2026 Dial-in: 1-800-579-2543 or 1-785-424-1789 (for international callers) Conference ID: TECHQ2 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and r
MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CST to review its second quarter fiscal 2026 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 4, 2026 Dial-in: 1-800-579-2543 or 1-785-424-1789 (for international callers) Conference ID: TECHQ2 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and r
MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2025. First Quarter FY2026 Highlights First quarter reported and organic revenue decreased 1% to $286.6 million.GAAP earnings per share (EPS) was $0.24 versus $0.21 for first quarter 2025. Delivered adjusted EPS of $0.42 compared to $0.42 for first quarter 2025.Completed the divestiture of the Exosome Diagnostics business including the ExoDx Prostate test (EPI) as the Company emphasizes investment and commercial priorities on non-CLIA based product lines in their growth pillars. Ongoing productivity and cost containment initiatives led
MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s
MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D
SC 13G - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)